Pier Capital LLC Has $4.32 Million Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Pier Capital LLC cut its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 102,128 shares of the company’s stock after selling 1,335 shares during the period. Pier Capital LLC’s holdings in Vera Therapeutics were worth $4,319,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. AlphaQuest LLC bought a new stake in shares of Vera Therapeutics during the 4th quarter worth approximately $34,000. KBC Group NV increased its holdings in Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after buying an additional 1,387 shares during the last quarter. Moors & Cabot Inc. bought a new stake in Vera Therapeutics during the fourth quarter worth $220,000. E Fund Management Co. Ltd. lifted its stake in Vera Therapeutics by 22.3% in the fourth quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock valued at $262,000 after acquiring an additional 1,130 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. grew its position in shares of Vera Therapeutics by 109.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 9,407 shares of the company’s stock valued at $416,000 after acquiring an additional 4,914 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on VERA. Wolfe Research assumed coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price on the stock. JPMorgan Chase & Co. reduced their price objective on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a report on Tuesday, March 4th. The Goldman Sachs Group began coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $58.00 price target on the stock. Finally, Guggenheim increased their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $64.67.

Vera Therapeutics Stock Up 0.3 %

Shares of NASDAQ VERA opened at $27.15 on Tuesday. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -10.40 and a beta of 1.17. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average price of $31.50 and a two-hundred day moving average price of $39.20. Vera Therapeutics, Inc. has a 12 month low of $25.99 and a 12 month high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. As a group, analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Activity

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the sale, the chief executive officer now owns 143,603 shares of the company’s stock, valued at approximately $5,993,989.22. This represents a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 21.70% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.